Quick Overview
This was a week of sharp contrasts in nicotine policy. The FDA took its most significant science-based step for harm reduction by granting MRTP status to 20 Zyn products, the first nicotine pouch brand authorized to tell consumers it’s less risky than smoking. But at the same time, the agency proposed a sweeping new rule targeting foreign manufacturers (read: Chinese disposable vape makers), the 5th Circuit ruled that HHS can’t fine vape retailers without a jury trial, and multiple countries from Russia to Pakistan tightened restrictions on safer alternatives. The core tension is clearer than ever: regulators can’t decide whether they’re fighting smoking or fighting nicotine.
1. FDA Grants MRTP Orders for 20 Zyn Products: First Nicotine Pouch With Reduced-Risk Claims
The FDA authorized Swedish Match USA to market 20 Zyn nicotine pouch products (10 flavors, 3mg and 6mg strengths) with modified-risk claims. This is the first nicotine pouch brand to receive MRTP status. The authorized claim states that using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The authorization requires post-market surveillance and behavioral studies, and the orders expire after 5 years unless renewed. PMI U.S. CEO Stacey Kennedy called it a milestone that provides adult consumers with FDA-reviewed, science-based information.
This creates a regulatory template for other pouch brands to follow. The question is whether the FDA will apply the same standard to vaping products, or whether pouches get special treatment because they don’t involve inhalation. We covered the Zyn MRTP announcement in detail here.
2. FDA Proposes Rule Requiring Foreign Tobacco Manufacturers to Register Facilities
The FDA published a proposed rule (21 CFR Part 1108) that would require foreign tobacco product manufacturers to register facilities and list products intended for U.S. distribution, closing a regulatory gap that has existed since the 2009 Tobacco Control Act. The rule would extend to foreign establishments manufacturing ENDS, e-cigarettes, and other tobacco products. Foreign manufacturers would be subject to FDA inspection. The expanded “manufacturer” definition includes specification developers, contract manufacturers, and repackagers. Public comments are open through September 14.
This is squarely aimed at Chinese disposable vape manufacturers who have been operating outside FDA’s direct oversight. The Premium Cigar Association has already signaled opposition, warning of significant compliance costs for small businesses. For context on what’s currently authorized, see our FDA authorized vapes list.
Source: Tobacco Reporter | Federal Register
3. 5th Circuit Rules HHS Can’t Impose Civil Penalties on Vape Retailer Without Jury Trial
A divided Fifth Circuit panel vacated a $19,192 civil penalty against Texas Tobacco Barn, ruling the company was entitled to a jury trial under the Seventh Amendment. The court found HHS could not impose civil monetary penalties through administrative proceedings without a jury trial, citing recent Supreme Court precedent. The decision could have broader implications for federal agency enforcement in tobacco and vaping cases. However, the court rejected the company’s separate challenge to FDA’s authority to regulate vaping products.
This is the kind of legal development that doesn’t make headlines but quietly shifts the balance of power between regulators and businesses. If other circuits follow, the FDA may need to rethink its enforcement playbook.
4. Australia’s $7 Billion Illicit Market: Etomidate-Laced Vapes Found in Melbourne
Victoria Health issued an urgent warning after vape products sold as “space vapes” tested positive for etomidate, a hospital-grade anaesthetic. ABS data shows 80% of nicotine consumed in Australia is now illicit, up from 12% eight years ago. Organized crime is deeply involved, with firebombings of tobacconists becoming common. University of Bath research found roughly 25% of devices confiscated in schools contained synthetic cannabinoids.
Australia’s prohibition experiment continues to produce exactly what experts predicted: a booming black market with contaminated products. The etomidate finding is particularly alarming. This is not a contaminant that appears by accident. The situation mirrors what we’ve seen in other prohibitionist approaches to nicotine regulation.
Source: Vaping Post | Victoria Health Alert
5. UK Disposable Vape Ban One Year Later: Smoking Rates Rise From 14% to 16%
An ELFBAR/Opinium survey of 6,000 UK adults found that 72% of daily disposable vapers shifted to refillable or reusable devices. But 1 in 6 former disposable users returned to smoking or started smoking more. Smoking rates jumped from 14% (2024) to 16% (2026). A University of Bristol study published in PLOS Global Public Health confirmed that dual users were likely to smoke more rather than switch to other vaping options. Over half of respondents now believe vaping is equally or more harmful than smoking, a perception shift that undermines public health messaging.
The UK ban was supposed to be a model for the world. One year in, the data tells a different story: the ban reduced disposable use but pushed a significant minority back to smoking, and public perception of relative risk has actually worsened. For more on the UK approach, see our analysis of the UK generational smoking ban.
6. Russia Signs New Tobacco Licensing Laws: Regional Vape Ban Pilot Approved
President Putin signed legislation introducing a licensing system for wholesale and retail sale of tobacco and nicotine products, with separate licenses required for each retail outlet and delivery vehicle. The law also gives Russia’s regions authority to ban vape and e-liquid sales under a 5-year pilot program running from March 2027 to March 2032. Criminal penalties include fines and forced labor for large-scale unlicensed sales.
Russia’s approach is notable for its regional pilot structure, letting individual regions test vape bans before any national prohibition. This creates a natural experiment that could produce useful data, assuming the data is transparent.
7. Pakistan Hikes E-Liquid Tax 65% While Cutting Cigarette Input Tax
Pakistan’s Federal Budget 2026-27 increased federal excise duty on e-liquids from Rs10,000 to Rs16,500/kg ($36 to $59.40), a 65% increase. At the same time, the government reduced duty on acetate tow (a cigarette filter input) from Rs44,000 to Rs10,000/kg. Cigarette excise rates have remained unchanged since February 2023. The Sustainable Development Policy Institute questioned the coherence of the tax policy.
Taxing safer alternatives at higher rates than combustible cigarettes is a pattern we’re seeing across multiple developing economies. It’s hard to call this anything other than policy incoherence (or worse, deliberate protection of cigarette tax revenue).
Weekly Trends & Analysis
The dominant theme this week is what I’d call regulatory schizophrenia. The FDA simultaneously took its most pro-harm-reduction step ever (Zyn MRTP) and its most aggressive enforcement-expansion step (foreign manufacturer registration). These aren’t contradictory per se, both are within the FDA’s statutory framework — but they reveal an agency that still hasn’t settled on a coherent philosophy.
Meanwhile, the 5th Circuit’s jury trial ruling adds a wildcard. If agencies can’t impose civil penalties without jury trials, the entire enforcement apparatus for tobacco regulation gets more expensive and slower. That’s good for due process but bad for swift enforcement against bad actors.
The international picture is equally mixed. The UK ban’s one-year data is a cautionary tale for every jurisdiction considering similar measures. Australia’s crisis deepens. Russia and Pakistan are moving in the wrong direction on harm reduction. But the Zyn MRTP shows that science-based regulation is still possible, at least for products that don’t involve inhalation. For a broader look at how these trends connect, see our coverage of the expanding war on nicotine.
What to Watch Next Week
- FDA comment period on foreign manufacturer rule: The 75-day comment window opened this week. Expect organized opposition from industry groups and possibly from foreign governments.
- Zyn MRTP post-market requirements: The behavioral studies and surveillance required by the FDA will set precedent for future MRTP applications from other pouch and vape brands.
- 5th Circuit en banc review?: The HHS civil penalty ruling is significant enough that either the full 5th Circuit or the Supreme Court may take it up.
- UK smoking rate trend: Watch for additional data points on whether the 14% to 16% increase is a blip or a trend.
- Norwich £5 vape deposit proposal: The city council’s deposit scheme for vape disposal could set a precedent for other UK municipalities.
Kevin Li — Founder & Editor, VapeObservation.com Kevin reviews vape products hands-on, prioritizing real-world performance over manufacturer claims. His goal: honest, practical advice that helps everyday vapers make informed choices. Before launching VapeObservation, he was a longtime vaper frustrated by promotional content disguised as reviews. Every article on the site reflects his commitment to data-driven, reader-first testing.
